Is the American Cancer Society more interested in cancer profit than cancer prevention?
A staggering 1.37 million new cases of cancer will be diagnosed in calendar 2005. That statistic was taken straight from the American Cancer Society's own reports. Given the crushing impact of cancer on public health, coupled with the ineffectiveness of measures like chemotherapy and radiation, you'd think that agencies like the American Cancer Society (ACS) would clamor for the chance to investigate new methods for preventing and combating the disease. Unfortunately, you might be wrong.
In this article, we'll explore how agencies like the ACS have an eye for their own financial interests. Why does the ACS reportedly put far greater financial emphasis on chemotherapy and radiation research than on life-saving prevention techniques? Why does the ACS appear to discredit physicians researching and practicing effective alternative cancer-fighting techniques? A closer look at the American Cancer Society reveals the agency's ties to the cancer industry.
Conflicts of Interest: Why the ACS stresses treatment and screening over prevention
So what are the American Cancer Society's strategies for fighting cancer? Innocent Casualties author Elaine Feuer comments that the ACS is more intent on developing cancer treatments than preventing the disease. Feuer argues, "Instead of allotting money towards the prevention of cancer, the medical establishment prescribes chemotherapy and radiation (which can be very expensive and even toxic)."
Also contentious is the agency's emphasis on screening. Samuel S. Epstein, author of The Politics of Cancer, argues that the society's "priorities remain fixated on damage control -- screening, diagnosis, and treatment." Sure enough, the ACS' 2005 Cancer Prevention and Early Detection Facts and Figures report focuses primarily on screening. While screenings are valuable in helping people fight cancer, they do not prevent the disease. If decreasing the number of cancer fatalities is the first priority, why not prevent the disease before it starts?
Many critics of the American Cancer Society are quick to suggest its "vested interest" in the cancer industry, especially in chemotherapy and pharmaceutical treatments. Dr. Samuel Epstein, former head of a Congressional committee on cancer, has accused the ACS of foul play for years. Epstein claims that the ACS' "longstanding conflicts of interest with a wide range of industries, coupled with a systematic discrediting of evidence of avoidable causes of cancer" preclude many powerful life-saving initiatives.
In a debate this year, Dr. Michael Thun of the American Cancer Society did not deny the agency's connection to corporate interests. “The American Cancer Society views relationships with corporations as a source of revenue for cancer prevention,” said Dr. Thun. “That can be construed as an inherent conflict of interest, or it can be construed as a pragmatic way to get funding to support cancer control.”
More articles:
|
